Background: Articular involvement is a frequent and invalidating manifestation in patients with Systemic Lupus Erythematosus (SLE) ranging from arthralgia to erosive arthritis. Bone erosions are far less common in SLE but require a different management and may display a distinct pathogenesis. Musculoskeletal ultrasonography (MSUS) has proven useful in the assessment of inflammatory arthritis and it is now known that MSUS is more sensitive than radiography in detecting bone erosions. Objectives: We aimed at analyzing, in a large monocentric cohort of SLE patients who suffered from arthritis, the relationship between 31 polymorphisms in 18 genes previously associated with SLE or other autoimmune/inflammatory arthritis [1] and the presence of bone erosions detected by MSUS. Methods: Consecutive SLE patients who complained articular involvement (defined by 1997 ACR criteria, i.e. ≥2 joints with tenderness, swelling or effusion) were enrolled. Patients RF+ve and/or anti-CCP+ve were excluded. Thirty-one SNPs in 18 genes (STAT4, IL10, IL23R, IRAK1, PSORS1C1, HCP5, MIR146a, PTPN2, ERAP1, ATG16L1, IRGM, TRAF3IP2, VKORC1, CCR5, ATG5, TRAF6, TNFSF4, CD40) were genotyped by allelic discrimination assays. Bilateral highresolution MSUS of the hands and feet was performed. Erosion number was recorded, the presence of erosive damage was assessed with a dichotomous score. Results: Clinical and laboratory features of the 95 enrolled patients are described in table.
Background: Articular involvement is a frequent and invalidating manifestation in patients with Systemic Lupus Erythematosus (SLE) ranging from arthralgia to erosive arthritis. Bone erosions are far less common in SLE but require a different management and may display a distinct pathogenesis. Musculoskeletal ultrasonography (MSUS) has proven useful in the assessment of inflammatory arthritis and it is now known that MSUS is more sensitive than radiography in detecting bone erosions. Objectives: We aimed at analyzing, in a large monocentric cohort of SLE patients who suffered from arthritis, the relationship between 31 polymorphisms in 18 genes previously associated with SLE or other autoimmune/inflammatory arthritis [1] and the presence of bone erosions detected by MSUS. Methods: Consecutive SLE patients who complained articular involvement (defined by 1997 ACR criteria, i.e. ≥2 joints with tenderness, swelling or effusion) were enrolled. Patients RF+ve and/or anti-CCP+ve were excluded. Thirty-one SNPs in 18 genes (STAT4, IL10, IL23R, IRAK1, PSORS1C1, HCP5, MIR146a, PTPN2, ERAP1, ATG16L1, IRGM, TRAF3IP2, VKORC1, CCR5, ATG5, TRAF6, TNFSF4, CD40) were genotyped by allelic discrimination assays. Bilateral highresolution MSUS of the hands and feet was performed. Erosion number was recorded, the presence of erosive damage was assessed with a dichotomous score. Results: Clinical and laboratory features of the 95 enrolled patients are described in Background: Given the heterogeneity of clinical presentations, the diagnosis of Systemic Lupus Erythematosus (SLE) can be challenging, in particular in those patients presenting with early or incomplete disease, or with overlapping or atypical features. Autoantibodies (AABs) are important in aiding the clinical diagnosis of SLE, with some few AABs, anti-double-stranded DNA (dsDNA), anti-Smith (Sm), and anti-ribosomal P (riboP) being highly associated with SLE. As none of the traditional AABs has sufficient sensitivity to achieve diagnosis of SLE, current testing is based on measuring multiple AAB assays either in parallel or serial. We have recently identified novel AABs in SLE, which hold promise for improving diagnostic testing of SLE (1). We have developed quantitative ELISA-prototypes for five new AABs, which were tested in combination with traditional AABs. Objectives: The objectives of this study were to evaluate the diagnostic value of novel AABs and to screen for an optimized combination of novel and traditional AABs using logistic regression to increase the diagnostic accuracy of SLE testing. Methods: Serum samples were obtained from 156 SLE patients with European ancestry at the rheumatology department of the Heinrich-Heine University (Düsseldorf, Germany), and Hannover Medical School (Hannover, Germany). SLE samples were compared against 126 samples from autoimmune diseases (AID; myositis: n=20; Sjögren's syndrome (SjS): n=31; rheumatoid arthritis (RA) n=36; systemic sclerosis (SSc): n=39), and 77 healthy control samples. Prototype bead based ELISAs were developed for five novel antigens described in (1). Traditional diagnostic AABs were measured using IVD ELISAs and included: SSA/Ro60, SSA/Ro52, La/SSB, Sm, RNP, dsDNA, Scl70, CENPB, Jo-1, CCP, phospholipid and dsDNA. Optimized marker combinations of new and traditional markers were tested using logistic regression and receiver operating curve analysis (ROC). Results: When comparing 156 SLE patients with 203 control samples, the area under the curve (AUC) of the five novel SLE ELISAs ranged from 0.63 to 0.75. A cut-off was set at a specificity of 95% and yielded a sensitivity ranging from 13.5% to 21.2% for the five novel assays. The sensitivity and specificity of new ELISAs was comparable to traditional ELISAs, which was in this cohort for anti-dsDNA 35% and 97%, anti-Sm 15% and 97%, and anti-RiboP 26% and 97%. A logistic regression model was used to combine the results of multiple tests. Compared to a logistic regression with traditional assays, a logistic regression with novel markers achieved higher sensitivity by pertaining high specificity. The logistic regression model based on a multimarker IVD assay with ten extracted nuclear antigens (ENA) yielded an AUC of 0.87 and a sensitivity of 58% at a specificity of 95%. By contrast, the optimal combination of traditional and novel ELISAs reached an AUC of 0.92 and a sensitivity of 75% at a specificity of 95%. Conclusions: This study demonstrates the feasibility of combining test results of novel and traditional AABs using logistic regression to increase the diagnostic accuracy for SLE. Further studies are required to assess the impact of different ethnicities on marker selection and algorithm performance. Background: Ultrasound of the major salivary glands (SGUS) has shown high diagnostic accuracy for primary Sjögren's syndrome (pSS) [1, 2] . None of the existing studies, however, included a control group of patients with sarcoidosis, amyloidosis, human immunodeficiency virus (HIV) or hepatitis C (HCV) infection [2] . These diseases are known to frequently affect the major salivary glands, cause dry mouth or may have histopathology similar to pSS. Objectives: To assess the diagnostic accuracy of SGUS to differentiate pSS from systemic diseases with salivary gland involvement. Methods: Twenty consecutive patients fulfilling the AECG criteria for pSS and 20 consecutive patients with well-established systemic diseases, i.e., 5 patients with sarcoidosis, 5 patients with amyloidosis, 5 patients with HIV infection and 5 patients with HCV infection, were included. Echogenicity, parenchymal homogeneity, presence of hypoechogenic areas and clearness of posterior glandular border of both parotid and submandibular salivary glands were scored independently by two blinded observers and rated according to the Hocevar et al scoring system (ultrasound total score (UTS), range: 0-48) [3] . The optimal cut-off point was determined by using ROC curve. The agreement between SGUS positivity and classification as pSS was assessed. Results: The median age of patients with pSS and systemic diseases was 50 and 53 years, respectively. Daily complaints of dry mouth longer than 3 months, need of liquid to swallow food and recurrent or persistent swelling of the major salivary glands were reported by 95%, 85% and 70% of patients with pSS compared to 45%, 30% and 20% of patients with systemic diseases. The accuracy of SGUS to discriminate pSS was excellent, with an area under ROC of 0.91 and optimal cut off point of 15. The agreement between SGUS and diagnosis for pSS was good (κ=0.75, percentage of absolute agreement 87.5) with a sensitivity of 90%,
